NCT05985811 Ketamine Enhances Analgesia and Mood in Chronic Pain Patients
| NCT ID | NCT05985811 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Salem Anaesthesia Pain Clinic |
| Condition | Mood Disorder; Opioid |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2018-02-02 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2018-02-02 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Most chronic pain patients have mood disorders. The mood disorders may improve with better analgesia produced by Ketamine injections. A prospective study of patients undergoing interventional pain therapy using Ketamine injections. Pre-injection and post-injection patient data is collected. Pain is measured using numeric pain rating scale, and change in pain score by 2-points is considered significant. Sleep is measured using Likert sleep scale, and change in sleep score by 2-points is considered significant. Anxiety is measured using general anxiety disorder (GAD-7) scale, and change in anxiety score by 4-points is considered significant. Depression is measured using patient health questionnaire (PHQ-9), and change in depression score by 5-points is considered significant.
Eligibility Criteria
Inclusion Criteria: * adult chronic pain patients * associated mood disorder * good treatment compliance * associated chronic insomnia * regular ketamine pain therapy injection * consent for clinical record quality assurance review Exclusion Criteria: * severe cognitive disorder * inability to provide consent * major neuropsychiatric disorder * cannabis use * stimulant use * substance abuse * poor treatment compliance * lack of ketamine pain therapy injection
Contact & Investigator
Olumuyiwa Bamgbade, MD,FRCPC
PRINCIPAL INVESTIGATOR
Salem Anaesthesia Pain Clinic
Frequently Asked Questions
Who can join the NCT05985811 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 99 Years, studying Mood Disorder; Opioid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05985811 currently recruiting?
Yes, NCT05985811 is actively recruiting participants. Contact the research team at salem.painclinic@gmail.com for enrollment information.
Where is the NCT05985811 trial being conducted?
This trial is being conducted at Surrey, Canada.
Who is sponsoring the NCT05985811 clinical trial?
NCT05985811 is sponsored by Salem Anaesthesia Pain Clinic. The principal investigator is Olumuyiwa Bamgbade, MD,FRCPC at Salem Anaesthesia Pain Clinic. The trial plans to enroll 500 participants.